Leading Players in the GLP-1 Market Novo Nordisk 38.72% Ozempic Wegovy Rybelsus Eli Lilly 28.41% Mounjaro Zepbound Sanofi 8.76% 4 AstraZeneca 6.62% 5 GSK 4.95% 6 Regeneron 3.27% 7 Pfizer 2.61% 8 Amgen 1.98% 9 Sun Pharma 1.52% Boehringer Ingelheim 1.24% Together, Novo Nordisk and Eli Lilly account for more than 67% of the market, highlighting the intense competition between the two companies that currently lead the obesity and diabetes treatment revolution
[13] [14] [15] Adverse effects and safety profile [edit] Semaglutide can cause a variety of side effects
Without coverage, the savings card still reduces your cost by up to $463 per month
Their invaluable contributions, commitment, and dedication are sincerely appreciated and were the key to the successful completion of this study
When searching for fish and beef, grass-fed beef and smaller fish are recommended over other types
The more time stool remains in the colon, the drier it becomes